Xenon Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. said premarket Tuesday that their mid-stage nerve pain drug missed its primary endpoint and secondary endpoints. Xenon shares were halted before the news, while Teva shares slumped 0.2% in premarket trade. The companies are evaluating next steps for the drug, TV-45070, which is intended for post-herpetic neuralgia, a painful complication of shingles. Xenon shares have plummeted 16.5% over the last three months to $3.80, while Teva shares have declined 0.2%, compared with a 4.2% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News